191 related articles for article (PubMed ID: 33378988)
1. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
[TBL] [Abstract][Full Text] [Related]
2. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
[TBL] [Abstract][Full Text] [Related]
3. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
5. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
[TBL] [Abstract][Full Text] [Related]
7. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
[TBL] [Abstract][Full Text] [Related]
8. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
Bai HY; Mogi M; Nakaoka H; Kan-No H; Tsukuda K; Chisaka T; Wang XL; Kukida M; Shan BS; Yamauchi T; Higaki A; Iwanami J; Horiuchi M
Eur J Pharmacol; 2015 Sep; 762():293-8. PubMed ID: 26057694
[TBL] [Abstract][Full Text] [Related]
10. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
11. LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Chang PC; Lin SF; Chu Y; Wo HT; Lee HL; Huang YC; Wen MS; Chou CC
Cardiovasc Ther; 2019; 2019():6032631. PubMed ID: 31772612
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis.
Shen JF; Fan ZB; Wu CW; Qi GX; Cao QY; Xu F
Oxid Med Cell Longev; 2022; 2022():5009289. PubMed ID: 36193085
[TBL] [Abstract][Full Text] [Related]
13. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
14. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Tao ZW; Huang YW; Xia Q; Xu QW
Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
[TBL] [Abstract][Full Text] [Related]
16. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
[TBL] [Abstract][Full Text] [Related]
18. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Sun J; Xu W; Hua H; Xiao Y; Chen X; Gao Z; Li S; Jing X; Du F; Sun G
Biomed Pharmacother; 2020 Sep; 129():110410. PubMed ID: 32570118
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
